Obesity Pillars最新文献

{"title":"Patient perceptions of three-dimensional (3D) surface imaging technology and traditional methods used to assess anthropometry","authors":"Lucie Nield ,&nbsp;Michael Thelwell ,&nbsp;Audrey Chan ,&nbsp;Simon Choppin ,&nbsp;Steven Marshall","doi":"10.1016/j.obpill.2024.100100","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100100","url":null,"abstract":"<div><h3>Background</h3><p>Obesity and overweight are commonplace, yet attrition rates in weight management clinics are high. Traditional methods of body measurement may be a deterrent due to invasive and time-consuming measurements and negative experiences of how data are presented back to individuals. Emerging new technologies, such as three-dimensional (3D) surface imaging technology, might provide a suitable alternative. This study aimed to understand acceptability of traditional and 3D surface imaging-based body measures, and whether perceptions differ between population groups.</p></div><div><h3>Methods</h3><p>This study used a questionnaire to explore body image, body measurement and shape, followed by a qualitative semi-structured interview and first-hand experience of traditional and 3D surface imaging-based body measures.</p></div><div><h3>Results</h3><p>49 participants responded to the questionnaire and 26 participants attended for the body measurements and interview over a 2-month period. There were 3 main themes from the qualitative data 1) Use of technology, 2) Participant experience, expectations and perceptions and 3) Perceived benefits and uses.</p></div><div><h3>Conclusion</h3><p>From this study, 3D-surface imaging appeared to be acceptable to patients as a method for anthropometric measurements, which may reduce anxiety and improve attrition rates in some populations. Further work is required to understand the scalability, and the role and implications of these technologies in weight management practice. (University Research Ethics Committee reference number ER41719941).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100100"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000020/pdfft?md5=9dab2a1581b7d3d2e928b4fa76354a34&pid=1-s2.0-S2667368124000020-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of phentermine / topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study","authors":"Harold E. Bays ,&nbsp;Daniel S. Hsia ,&nbsp;Lan T. Nguyen ,&nbsp;Craig A. Peterson ,&nbsp;Santosh T. Varghese","doi":"10.1016/j.obpill.2024.100099","DOIUrl":"10.1016/j.obpill.2024.100099","url":null,"abstract":"<div><h3>Background</h3><p>A fixed-dose combination of phentermine and extended-release topiramate (PHEN/TPM - approved for weight management) has demonstrated in-clinic reduction of blood pressure (BP). Ambulatory BP monitoring (ABPM) may be a better predictor of cardiovascular disease risk than in-clinic BP.</p></div><div><h3>Methods</h3><p>This randomized, multicenter, double-blind study enrolled 565 adults with overweight/obesity. Inclusion criteria included participants willing to wear ABPM device for 24 h. Exclusion criteria included screening blood pressure &gt;140/90 mmHg and antihypertensive medications not stable for 3 months prior to randomization. Participants received placebo (n = 184), phentermine 30 mg; (n = 191), or PHEN 15 mg/TPM 92 mg; (n = 190). 24-hour ABPM was performed at baseline and at week 8. The primary endpoint was mean 24-h systolic BP (SBP) as measured by ABPM, in the per protocol population.</p></div><div><h3>Results</h3><p>Participants were mostly female (73.5 ​%) and White (81.6 ​%), with a mean age of 53.4 years; 32.4 ​% had no hypertension diagnosis or treatment, 62.5 ​% had hypertension using 0 to 2 antihypertensive medications, and 5.1 ​% had hypertension using ≥ 3 antihypertensive medications. Baseline mean SBP/diastolic BP (DBP) was 123.9/77.6 ​mmHg. At week 8, mean SBP change was −0.1 ​mmHg (placebo), +1.4 ​mmHg (phentermine 30 ​mg), and −3.3 ​mmHg (PHEN/TPM). Between-group difference for PHEN/TPM versus placebo was −3.2 ​mmHg (95 ​% CI: -5.48, -0.93 ​mmHg; p ​= ​0.0059). The between-group difference for PHEN/TPM versus phentermine 30 ​mg was −4.7 ​mmHg (95 ​% CI: −6.96, −2.45 ​mmHg; p ​&lt; ​0.0001). Common (&gt;2 ​% in any treatment group) adverse events (i.e., dry mouth, constipation, nausea, dizziness, paresthesia, dysgeusia, headache, COVID-19, urinary tract infection, insomnia, and anxiety) were mostly mild or moderate.</p></div><div><h3>Conclusions</h3><p>In this randomized, multicenter, double-blind ABPM study, PHEN/ TPM reduced SBP compared to either placebo or phentermine 30 mg (Funding: Vivus LLC; ClinicalTrials.gov: <span>NCT05215418</span><svg><path></path></svg>).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100099"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000019/pdfft?md5=af3a54e4dff0c78a5b9dd3deedb8b337&pid=1-s2.0-S2667368124000019-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139455543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes","authors":"Rieko Kanai ,&nbsp;Sachiho Kinoshita ,&nbsp;Izumi Kanbe ,&nbsp;Mariko Sameda ,&nbsp;Shuhei Yamaoka ,&nbsp;Osamu Horikawa ,&nbsp;Yasuhiro Watanabe ,&nbsp;Ichiro Tatsuno ,&nbsp;Kohji Shirai ,&nbsp;Takashi Oshiro ,&nbsp;Atsuhito Saiki","doi":"10.1016/j.obpill.2023.100098","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100098","url":null,"abstract":"<div><h3>Background</h3><p>Glucagon-like peptide (GLP)-1 analogue may be useful for controlling weight recurrence and diabetes relapse after bariatric surgery, but may also adversely affect the measured nutritional metrics. This study aimed to investigate the effect of treatment with once-weekly semaglutide after laparoscopic sleeve gastrectomy (LSG) in patients with type 2 diabetes (T2D). We also examined the effects of combined use with a low-energy, high-protein formula diet (FD).</p></div><div><h3>Methods</h3><p>This study was a single-center retrospective database analysis. We enrolled 29 Japanese patients with T2D who underwent LSG, and more than 12 months later received semaglutide. The patients were divided retrospectively into a FD group (=6) and a conventional diet (CD) group (n = 23).</p></div><div><h3>Results</h3><p>BMI and HbA1c decreased significantly by 10.7 kg/m² and 1.1 %, respectively, 12 months after LSG, and decreased by an additional 1.6 kg/m² and 0.6 % after 12-months of treatment with semaglutide. Decreases in serum albumin, vitamin B12 and zinc were observed only after semaglutide administration. A ratio of energy from protein, fat and carbohydrates changed from 13:31:56 before to 19:30:50 after LSG, and from 17:32:51 before to 15:29:56 after semaglutide. Skeletal muscle ratio, which is the ratio of skeletal muscle mass to body weight, increased after LSG, but did not change after semaglutide. FD group showed a significant increase in skeletal muscle mass per 1 % body weight compared to CD group during semaglutide treatment.</p></div><div><h3>Conclusion</h3><p>Semaglutide after LSG in patients with obesity and T2D resulted in additional weight reduction and improved glycemic control, but worsened measured nutritional metrics. Administration of a low-energy, high protein formula diet may ameliorate adverse nutritional effects of semaglutide in patients with T2D after LSG. (Ethics Committee of Toho University Sakura Medical Center approval number S18061)</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100098"},"PeriodicalIF":0.0,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812300044X/pdfft?md5=58fd59fb154c5520c26884192b3feafe&pid=1-s2.0-S266736812300044X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139108935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Motivational interviewing for weight management among college students during COVID-19: An exploratory randomized controlled trial","authors":"Kameron B. Suire ,&nbsp;Jan Kavookjian ,&nbsp;Kamden Strunk ,&nbsp;Danielle D. Wadsworth","doi":"10.1016/j.obpill.2023.100097","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100097","url":null,"abstract":"<div><h3>Background</h3><p>College students encounter challenges in managing their weight. The Coronavirus Disease 2019 (COVID-19) pandemic exacerbated the problem. The purpose of this study was to determine the effect of a motivational interviewing (MI) intervention compared to online education (control) on body composition and self-determination theory constructs among college students with overweight.</p></div><div><h3>Methods</h3><p>This was a randomized clinical trial of 40 college students comparing an MI versus a control group. The MI group received monthly interviews: three face-to-face interviews before the pandemic, and three video chat interviews after the outbreak of COVID-19 spanning a total of six months. The control group received six, monthly education modules. Body composition was measured by the iDexa and self-determination theory (SDT) variables were assessed with surveys.</p></div><div><h3>Results</h3><p>Mixed ANOVAs from pre-post revealed significant changes in fat mass (p = .03, η² = 0.22), lean mass (p &lt; .05, η² = 0.18), body fat percentage (<em>p</em> &lt; .01, η² = 0.37), autonomy (p &lt; .01, η² = 0.38), relatedness (p &lt; .01, η² = 0.41), amotivation (p = .01, η² = 0.29), external regulation (p = .02, η² = 0.23), identified regulation (p = .02, η² = 0.25), integrated regulation (p &lt; .00, η² = 0.49), and intrinsic regulation (p = .01, η² = 0.27).</p></div><div><h3>Conclusions</h3><p>In this exploratory analysis, MI demonstrated a positive trend in body composition maintenance when compared to online education among overweight college students during a national pandemic. Future studies utilizing MI would enhance the literature by further investigating the relationship between MI and SDT and measuring body composition.</p><p>Clinicaltrials.gov. identifier: NCT04130386.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368123000438/pdfft?md5=9433796914156168668f05039cbdc084&pid=1-s2.0-S2667368123000438-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139099852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special considerations for the adolescent with obesity: An obesity medicine association (OMA) clinical practice statement (CPS) 2024","authors":"Suzanne Cuda,&nbsp;Valerie O'Hara,&nbsp;Marisa Censani,&nbsp;Rushika Conroy,&nbsp;Brooke Sweeney,&nbsp;Jennifer Paisley,&nbsp;Cristina Fernandez,&nbsp;Meredith L. Dreyer Gillette,&nbsp;Allen Browne,&nbsp;Nancy T. Browne","doi":"10.1016/j.obpill.2023.100096","DOIUrl":"10.1016/j.obpill.2023.100096","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details special considerations for the management of the adolescent with obesity. The information in this CPS is based on scientific evidence, supported by medical literature, and derived from the clinical experiences of members of the OMA.</p></div><div><h3>Methods</h3><p>The scientific information and clinical guidance in this CPS are based on scientific evidence, supported by the medical literature, and derived from the clinical perspectives of the authors.</p></div><div><h3>Results</h3><p>This OMA Clinical Practice Statement addresses special considerations in the management and treatment of adolescents with overweight and obesity.</p></div><div><h3>Conclusions</h3><p>This OMA Clinical Practice Statement on the adolescent with obesity is an overview of current recommendations. These recommendations provide a roadmap to the improvement of the health of adolescents with obesity, especially those with metabolic, physiological, and psychological complications. This CPS also addresses treatment recommendations and is designed to help the provider with clinical decision making.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"9 ","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368123000426/pdfft?md5=18918828608af28620ca022cef755555&pid=1-s2.0-S2667368123000426-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138612106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size","authors":"Haim Shirin ,&nbsp;Ian J. Neeland ,&nbsp;Donna H. Ryan ,&nbsp;Daniel de Luis ,&nbsp;Albert Lecube ,&nbsp;Zoltan Magos ,&nbsp;Yael Kenan ,&nbsp;Ruthie Amir ,&nbsp;Daniel L. Cohen ,&nbsp;Odd Erik Johansen","doi":"10.1016/j.obpill.2023.100094","DOIUrl":"10.1016/j.obpill.2023.100094","url":null,"abstract":"<div><h3>Background</h3><p>The Epitomee Capsule (EC) is an, oral, self‐use, bio-degradable device for weight management, composed of absorbent polymers that self-expands in the stomach (pH-sensitive) and creates a triangular shape, space-occupying super-absorbent gel structure. A recent study reported that 42 % of study completers obtained &gt;5 % weight reduction at 12 weeks. We performed exploratory analyses of this study to evaluate its effect on cardiovascular risk factors and on self-reported satiety, between-meal snacking and meal-size.</p></div><div><h3>Methods</h3><p>This single-center observational study (Israel) enrolled 78 volunteers, with mean age 41 years, BMI 32.5 kg/m², systolic/diastolic blood pressure (SBP/DBP) 124/77 mmHg. The EC was given in addition to diet and physical activity counseling. Assessments included anthropometrics, BP, lipids, and three questions (translated from Hebrew) scored 1 (not at all) to 5 (very much) for “Do you feel the EC - Q1:helps you to consume less snacks in between meals? Q2:helps you to eat less in the meal?; Q3:is causing an early sense of satiety?”. Changes from baseline were assessed using a mixed model and included all patients with at least one measure. Correlation-analysis between weight-change and PROs used Kendall's tau.</p></div><div><h3>Result</h3><p>Compared to baseline, at 12 weeks, SBP/DBP were reduced (ΔSBP: −5.5 mmHg, p = 0.0003/ΔDBP: −1.9 mmHg, p = 0.1341), with a larger effect in people with hypertension at baseline (ΔSBP: −13.2 mmHg, p &lt; 0.00001/ΔDBP: −6.1, p = 0.008). Triglyceride-level was also significantly reduced, but not other lipids. Mean scores to Q1-3 were high throughout, with slight decreases (Q1 at W2 3.9 ± 1.1/W12 3.0 ± 1.6; Q2 at W2 3.7 ± 1.1/W12 3.1 ± 1.6; Q3 at W2 3.8 ± 1.2/W12 2.9 ± 1.6). There was a moderate correlation between PROs and weight reduction, although significance was not observed for all weeks.</p></div><div><h3>Conclusions</h3><p>Exploratory analyses of 12 weeks treatment with EC demonstrated significant reductions in SBP, DBP, and triglycerides. The weight reduction correlated with satiety, less snacking, and reduced meal size.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"8 ","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368123000402/pdfft?md5=f93364a4e35d4488509f7648346f5244&pid=1-s2.0-S2667368123000402-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135715182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight reduction after bariatric surgery - Do results correlate with postoperative visit frequency?","authors":"Anila Punjwani ,&nbsp;Gabrielle Unbehaun ,&nbsp;Zachary Duarte ,&nbsp;Juaquito Jorge","doi":"10.1016/j.obpill.2023.100093","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100093","url":null,"abstract":"<div><h3>Background</h3><p>Consistent follow up after a bariatric surgery is considered vital to adequate and sustained weight reduction. This study examined the strength to which compliance with postsurgical appointments predicted an increase in total body weight loss percent (TBWL%) and change in body mass index (BMI) in a cohort of Illinois based surgical center patients.</p></div><div><h3>Methods</h3><p>Participants (n = 78) were patients with obesity who underwent bariatric surgery between 2019 and 2021. Patient preoperative weight and BMI, and postoperative weight and BMI at 3-month intervals for one year, and the number of visits were collected from chart review to calculate TBWL%, and change in BMI. Relationship between these factors and postoperative visit compliance were evaluated using linear regression to assess if it was a significant predictor of success.</p></div><div><h3>Results</h3><p>Follow up visit compliance had a weak positive association with increased TBWL% (Model R² = 0.134, B = 0.011, p = 0.004) and a minimally stronger association with increased change in BMI (Model R² = 0.229, B = 0.015, p = 0.0001).</p></div><div><h3>Conclusions</h3><p>Adherence with follow up visits was weakly related to improved weight reduction outcomes after bariatric surgery. Future investigations should consider how follow up visits can better influence a patient's success in sustaining achieved weight reduction.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"8 ","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368123000396/pdfft?md5=f464625d1ef6910b56c813a2e2eaf5fd&pid=1-s2.0-S2667368123000396-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134657057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: An obesity medicine association (OMA) clinical practice statement (CPS) 2023","authors":"Shagun Bindlish,&nbsp;Jennifer Ng,&nbsp;Wissam Ghusn,&nbsp;Angela Fitch,&nbsp;Harold Edward Bays","doi":"10.1016/j.obpill.2023.100092","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100092","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians with an overview on obesity, thrombosis, venous disease, lymphatic disease, and lipedema.</p></div><div><h3>Methods</h3><p>The scientific support for this CPS is based upon published citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.</p></div><div><h3>Results</h3><p>Topics in this CPS include obesity, thrombosis, venous disease, lymphatic disease, and lipedema. Obesity increases the risk of thrombosis and cardiovascular disease via fat mass and adiposopathic mechanisms. Treatment of thrombosis or thrombotic risk includes healthful nutrition, physical activity, and the requisite knowledge of how body weight affects anti-thrombotic medications. In addition to obesity-related thrombotic considerations of acute coronary syndrome and ischemic non-hemorrhagic stroke, this Clinical Practice Statement briefly reviews the diagnosis and management of clinically relevant presentations of deep vein thromboses, pulmonary embolism, chronic venous stasis, varicose veins, superficial thrombophlebitis, lipodermatosclerosis, corona phlebectatica, chronic thromboembolic pulmonary hypertension, iliofemoral venous obstruction, pelvic venous disorder, post-thrombotic syndrome, as well as lymphedema and lipedema – which should be included in the differential diagnosis of other edematous or enlargement disorders of the lower extremities.</p></div><div><h3>Conclusions</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) on obesity, thrombosis, and venous/lymphatic disease is one of a series of OMA CPSs designed to assist clinicians in the care of patients with the disease of obesity.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"8 ","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368123000384/pdfft?md5=f632946dd26048d66d34a413694d941c&pid=1-s2.0-S2667368123000384-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91987012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming the landscape of obesity education - The Canadian obesity education competencies","authors":"Joseph Abraham Roshan ,&nbsp;Taniya S. Nagpal ,&nbsp;Nicole Pearce ,&nbsp;Khushmol K. Dhaliwal ,&nbsp;Mohamed El-Hussein ,&nbsp;Mary Forhan ,&nbsp;Stasia Hadjiyanakis ,&nbsp;Raed Hawa ,&nbsp;Robert F. Kushner ,&nbsp;Dayna Lee-Baggley ,&nbsp;Michelle McMillan ,&nbsp;Sarah Nutter ,&nbsp;Helena Piccinini-Vallis ,&nbsp;Michael Vallis ,&nbsp;Sean Wharton ,&nbsp;David Wiljer ,&nbsp;Sanjeev Sockalingam","doi":"10.1016/j.obpill.2023.100091","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100091","url":null,"abstract":"<div><h3>Background</h3><p>With ongoing gaps in obesity education delivery for health professions in Canada and around the world, a transformative shift is needed to address and mitigate weight bias and stigma, and foster evidence-based approaches to obesity assessment and care in the clinical setting. Obesity Canada has created evidence-based obesity competencies for medical education that can guide curriculum development, assessment and evaluation and be applied to health professionals' education programs in Canada and across the world.</p></div><div><h3>Methods</h3><p>The Obesity Canada Education Action Team has seventeen members in health professions education and research along with students and patient experts. Through an iterative group consensus process using four guiding principles, key and enabling obesity competencies were created using the 2015 CanMEDS competency framework as its foundation. These principles included the representation of all CanMEDS Roles throughout the competencies, minimizing duplication with the original CanMEDS competencies, ensuring obesity focused content was informed by the 2020 Adult Obesity Clinical Practice Guidelines and the 2019 US Obesity Medication Education Collaborative Competencies, and emphasizing patient-focused language throughout.</p></div><div><h3>Results</h3><p>A total of thirteen key competencies and thirty-seven enabling competencies make up the Canadian Obesity Education Competencies (COECs).</p></div><div><h3>Conclusion</h3><p>The COECs embed evidence-based approaches to obesity care into one of the most widely used competency-based frameworks in the world, CanMEDS. Crucially, these competencies outline how to address and mitigate the damaging effects of weight bias and stigma in educational and clinical settings. Next steps include the creation of milestones and nested Entrustable Professional Activities, a national report card on obesity education for undergraduate medical education in Canada, and Free Open Access Medication Education content, including podcasts and infographics, for easier adoption into curriculum around the world and across the health professions spectrum.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"8 ","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49700802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of an international pilot project to adapt the Canadian Adult Obesity Clinical Practice Guideline","authors":"Ximena Ramos Salas ,&nbsp;Miguel Alejandro Saquimux Contreras ,&nbsp;Cathy Breen ,&nbsp;Yudith Preiss ,&nbsp;Brad Hussey ,&nbsp;Mary Forhan ,&nbsp;Sean Wharton ,&nbsp;Denise Campbell-Scherer ,&nbsp;Michael Vallis ,&nbsp;Jennifer Brown ,&nbsp;Sue D. Pedersen ,&nbsp;Arya M. Sharma ,&nbsp;Euan Woodward ,&nbsp;Ian Patton ,&nbsp;Nicole Pearce","doi":"10.1016/j.obpill.2023.100090","DOIUrl":"https://doi.org/10.1016/j.obpill.2023.100090","url":null,"abstract":"<div><h3>Background</h3><p>The evidence-based Canadian Adult Obesity Clinical Practice Guideline (CPG) released in August 2020 were developed through a systematic literature review and patient-oriented research process. This CPG is considered a paradigm shift for obesity care as it introduced a new obesity definition that is based on health not body size, incorporates lived experiences of people affected by obesity, and addresses the pervasive weight bias and stigma that patients face in healthcare systems. The purpose of this pilot project was to assess the feasibility of adapting the Canadian CPG in Chile and Ireland.</p></div><div><h3>Methods</h3><p>An International Clinical Practice Guideline Adaptation Committee was established to oversee the project. The project was conducted through four interrelated phases: 1) planning and preparation; 2) pilot project application process; 3) adaptation; and 4) launch, dissemination, and implementation. Ireland used the GRADE-ADAPTE framework and Chile used the GRADE-ADOLOPMENT approach.</p></div><div><h3>Results</h3><p>Chile and Ireland developed their adapted guidelines in one third of the time it took to develop the Canadian guidelines. In Ireland, 18 chapters, which underpin the 80 key recommendations, were contextually adapted. Chile adopted 18 chapters and 76 recommendations, adapted one recommendation, and developed 12 new recommendations.\u2028</p></div><div><h3>Conclusion</h3><p>The pilot project demonstrated it is feasible to adapt the Canadian CPG for use in other countries with different healthcare systems, languages, and cultural contexts, while retaining the Canadian CPG's key principles and values such as the treatment of obesity as a chronic disease, adoption of new clinical assessment approaches that go beyond anthropometric measurements, elimination of weight bias and stigma, shifting obesity care outcomes to improved health and well-being rather than weight loss alone, and the use of patient-centred, collaborative and shared-decision clinical care approaches.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"8 ","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49700816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}